

Appl. No. 10/791,592  
Amdt. dated December 20, 2004  
Reply to Office Action of November 18, 2004

PATENT

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claim 1 (original): An antibody or binding fragment thereof which specifically binds MCP-1 receptor polypeptide, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

Claim 2 (original): The antibody of claim 1, wherein the antibody is labeled with a detectable label.

Claim 3 (original): The antibody of claim 2, wherein the detectable label is a radioactive isotope.

Claim 4 (original): The antibody of claim 1, wherein the antibody is a monoclonal antibody.

Claim 5 (original): The antibody of claim 1, wherein the antibody is a humanized antibody.

Claims 6-8 (canceled).

Claim 9 (withdrawn): A method of making an antibody that binds MCP-1 receptor polypeptide comprising:

- (a) immunizing an animal with the polypeptide comprising SEQ ID NO: 2;
- (b) isolating antibody-producing cells from the animal;
- (c) fusing the antibody-producing cells with immortalized cells in culture to form monoclonal antibody-producing hybridoma cells;
- (d) culturing the hybridoma cells; and
- (e) isolating from the culture monoclonal antibodies which specifically bind to the MCP-1 receptor polypeptide.

Appl. No. 10/791,592  
Amdt. dated December 20, 2004  
Reply to Office Action of November 18, 2004

PATENT

Claim 10 (original): A composition comprising an antibody according to claim 1, and a pharmaceutically acceptable carrier.

Claim 11 (original): The antibody of claim 1, wherein specific binding of the antibody or the binding fragment to the MCP-1 receptor polypeptide results in neutralization of activity of the MCP-1 receptor polypeptide.

Claim 12 (original): An antibody made by the method of claim 9.